Dr. Thomas Kollars, Chief Scientific Advisor for MIT Holding, Inc., Receives Department of Defense Results of the ProVector BtTM Mosquito Control Device

Business Wire, Feb 11, 2009

SAVANNAH, Ga. -- In blind trials conducted by the Department of Defense, the ProVector Bt(TM)killed 50 to 100% of the mosquitoes that transmit malaria and dengue within days. The ProVector Bt was also recently validated by Georgia Southern University. Dr. Kollars' work in developing the ProVector Bt formula is unique in that it is the first time anyone has been able to get mature mosquitoes to ingest and die from Bacillus thurengiensis (Bt), a safe biopesticide. Instead of spraying pesticides in the environment, the mosquitoes are attracted to the ProVector Bt and consume the formulation and die. It is a GREEN technology and is safe to use indoors and outdoors to kill mosquitoes, and it is harmless to pets, people and the environment. "It is quite a breakthrough...Dr. Kollars' finding is so interesting and important," said Dr. Margalit, the scientist who discovered Bt in the 1980s.

MIT Holding is looking for international distributors for the ProVector(TM) Bt. If you are interested in further information you can contact us at (912) 925-1905 or visit our website www.mitholding.com.

About MIT HOLDING

MIT through its wholly owned subsidiaries, based in Savannah, Georgia, provides medical services to Hospitals, Clinics, Doctor's offices and their Patients. Medical Infusion Technologies is a Pharmacy based infusion business. The licensed pharmacy can dispense infusible and non-infusible prescription pharmaceuticals to treat a wide range of chronic and acute health conditions. The home medical equipment division carries a wide variety of durable medical equipment and supplies for purchase or lease. The division maintains inventory and can rapidly obtain a wide variety of home medical equipment products to match almost any request. The Physician based Ambulatory Care Center provides eight on site intravenous suites for patients with a wide range of IV Therapy needs.